Atypical micromegakaryocytes, promegakaryoblasts and megakaryoblasts: a critical evaluation by immunohistochemistry, cytochemistry and morphometry of bone marrow trephines in chronic myeloid leukemia and myelodysplastic syndromes
- PMID: 1279889
- DOI: 10.1007/BF02899693
Atypical micromegakaryocytes, promegakaryoblasts and megakaryoblasts: a critical evaluation by immunohistochemistry, cytochemistry and morphometry of bone marrow trephines in chronic myeloid leukemia and myelodysplastic syndromes
Abstract
A morphometric analysis of bone marrow trephine biopsies has been performed to study the frequency and planimetric characteristics of so-called atypical micromegakaryocytes in chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS). In addition, an attempt was made to discriminate this particular cell population from small immature elements of megakaryocytopoiesis, such as promegakaryoblasts and megakaryoblasts. The staining reactions employed included periodic acid-Schiff (PAS), alpha-naphthyl acetate esterase (ANAE) and immunohistochemistry with a monoclonal antibody against platelet glycoprotein IIIa (Y2/51-CD61). Comparison of the various staining reactions applied to the different megakaryocytic elements together with morphometric measurements resulted in a clearcut identification of promegakaryoblasts. These were defined as the earliest immature and exclusively CD61-positive precursors. Atypical micromegakaryocytes were characterized by their dysplastic features and strong ANAE reactivity in addition to their positive CD61 staining. When stringent diagnostic criteria (diameter ranging between 10 to 15 microns, mean size about 12 microns) were applied, this abnormal cell population comprised less than 10% of total megakaryocytopoiesis in CML and MDS. It may be assumed that dysmegakaryocytic features in the latter disorders are partially generated by small to medium-sized megakaryocytes (diameter less than 30 microns). In conclusion, the relative frequency of promegakaryoblasts in the normal bone marrow (range 6-8%) is confirmed by evaluation of the immunohistochemical and cytochemical staining methods (CD61 and ANAE). Furthermore, the ANAE reaction facilitates the recognition of atypical micromegakaryocytes as well as small megakaryocytes. Thus cytochemistry provides a better insight into alterations of these cell lineages in various pathological conditions.
Similar articles
-
Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.J Clin Pathol. 1991 Apr;44(4):300-5. doi: 10.1136/jcp.44.4.300. J Clin Pathol. 1991. PMID: 2030148 Free PMC article.
-
[Importance of immunomorphometric evaluation of the size and number of megakaryocytes in normal and pathologic bone marrow].Srp Arh Celok Lek. 1993 Mar-Jul;121(3-7):57-61. Srp Arh Celok Lek. 1993. PMID: 7716637 Serbian.
-
Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.Mod Pathol. 2001 Feb;14(2):129-38. doi: 10.1038/modpathol.3880269. Mod Pathol. 2001. PMID: 11235904
-
Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.Histol Histopathol. 2004 Oct;19(4):1277-88. doi: 10.14670/HH-19.1277. Histol Histopathol. 2004. PMID: 15375771 Review.
-
Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.Pathobiology. 2007;74(2):97-114. doi: 10.1159/000101709. Pathobiology. 2007. PMID: 17587881 Review.
Cited by
-
Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes.Virchows Arch A Pathol Anat Histopathol. 1993;423(1):33-8. doi: 10.1007/BF01606429. Virchows Arch A Pathol Anat Histopathol. 1993. PMID: 8105604
-
[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].Pathologe. 2004 Nov;25(6):428-35. doi: 10.1007/s00292-004-0701-x. Pathologe. 2004. PMID: 15179523 German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous